<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Twenty-three patients with malignant glial <z:hpo ids='HP_0002664'>neoplasms</z:hpo> were treated with <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy for thromboembolic complications </plain></SENT>
<SENT sid="1" pm="."><plain>Fifteen patients had <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> alone, and 8 patients had both <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo> and <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Serum prothrombin times were maintained at 1.25 times control for an average of 5.8 months per patient, for a total patient exposure to <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy of 132 patient-months (11 patient-years) </plain></SENT>
<SENT sid="3" pm="."><plain>Only 1 patient suffered a recurrent <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo>, and this occurred during an episode of <z:hpo ids='HP_0002239'>gastrointestinal bleeding</z:hpo>, when <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy had to be discontinued prematurely </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients were followed with serial computed tomographic or magnetic resonance imaging scans, and no patient showed radiographic evidence of intratumoral <z:mp ids='MP_0001914'>hemorrhage</z:mp> either during or after <z:chebi fb="8" ids="10033">warfarin</z:chebi> therapy </plain></SENT>
<SENT sid="5" pm="."><plain>One patient, who died from a large recurrent <z:hpo ids='HP_0100843'>glioblastoma</z:hpo>, was found at autopsy to have scattered foci of intratumoral <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>This series, together with a review of the available literature, suggests that oral <z:chebi fb="3" ids="50249">anticoagulant</z:chebi> therapy is both a safe and effective means of treating thromboembolic complications in patients with residual <z:e sem="disease" ids="C0555198" disease_type="Neoplastic Process" abbrv="">malignant glial tumors</z:e> </plain></SENT>
</text></document>